Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia

Michele P Lambert1,2
1Division of Hematology, The Children’s Hospital of Philadelphia, 2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Abstract: Pediatric data on the use of thrombopoietin receptor agonists are fairly limited. The recent approval of eltrombopag by the US Food and Drug Administration for children aged ≥1 year, based on data from two randomized, placebo-controlled clinical trials, may lead to the increased use of this drug in clinical practice, and therefore, it is important to have a basic understanding of the biology, pharmacokinetics, safety, and efficacy of the medication.

Keywords: ITP, pediatrics, treatment, thrombopoietin receptor agonists

Introduction

Immune thrombocytopenia (ITP) is an autoimmune disease resulting in an isolated low platelet count (<100x10⁹/L) due to a variable combination of immune-mediated destruction of platelets by various mechanisms, impaired platelet production, and inappropriate thrombopoietin (TPO) response. ITP is defined as “newly diagnosed”, “persistent”, and “chronic” if it is diagnosed within the first 3 months, between 3 months and 12 months, and after >12 months, respectively. ITP occurs in 1.9–6.4 in 100,000 children, and it is generally found in a child who is otherwise well often presenting with the dramatic onset of bruising and petechiae and very low platelet count. The majority of these children, however, resolve spontaneously within a few weeks and do not require treatment. A few patients with significant hemorrhage may require therapies directed at raising the platelet count. Occasionally, patients with pediatric ITP require treatment with second-line therapies, which may include immunosuppressive therapies (such as rituximab, azathioprine, mercaptopurine, and sirolimus), splenectomy, or, more recently, TPO receptor agonists (RAs).

TPO was first identified in the year 1994 as the main regulator of platelet mass in the well state. TPO production appears to be constitutive in the liver and cleared primarily by binding to the TPO receptor (c-mpl) on platelets. Therefore, the TPO level increases as the platelet count decreases. Initial work to create first-generation TPO-RAs focused on recombinant protein technology, but was halted after some patients developed anti-bodies that cross-reacted with native TPO resulting in severe thrombocytopenia. The second-generation TPO RAs have been developed to avoid any of these complications and specifically lack any sequence homology with endogenous TPO.

Two TPO RAs have been studied in pediatric patients: romiplostim and eltrombopag. Eltrombopag (SB497115, Promacta, Revolade; GlaxoSmithKline plc, London, UK) was approved by the US Food and Drug Administration (FDA) for use in adults with chronic ITP in 2008 and in pediatric patients ≥1 year of age with chronic ITP.
who had had insufficient response to immunoglobulin, corticosteroids, or splenectomy, in August 2015. Eltrombopag, as the only TPO RA approved for use in pediatrics, is the focus of this review.

**Biology and dosing of eltrombopag**

Eltrombopag is a small molecule, non-peptide agonist that binds within the transmembrane domain of the TPO receptor resulting in signaling through the JAK/STAT and MAPK pathways similar to the signaling mechanism of TPO (Figure 1). It is a biphenyl hydrazone and is structurally distinct from endogenous TPO (Figure 2). Therefore, eltrombopag noncompetitively activates the TPO receptor by binding within the transmembrane domain to initiate the signaling cascade and cause both proliferation of megakaryocytes and differentiation resulting in generation of increased numbers of platelets. Eltrombopag is active only on human megakaryocytes. Because eltrombopag binds to a site distinct from endogenous TPO on c-mpl, the effects of eltrombopag in the presence of TPO signaling may be additive.

Eltrombopag is orally bioavailable and absorbed with peak absorption at 2–6 hours after administration. Food and polyvalent cations significantly decrease absorption (calcium, iron, magnesium), and therefore recommendations are that this medication should be taken on an empty stomach (at least 1 hour before or 2 hours after any meal) or at least 2 hours before or 4 hours after other medications, calcium-rich foods (dairy or calcium-fortified juices) or other supplements (particularly iron, selenium, zinc, and magnesium). The dietary restrictions can have a significant impact on patients’ ability to take the medication. Hepatic impairment significantly increased plasma levels and prolonged half-life.

Eltrombopag is currently available in several dosing tablets: 12.5 mg, 25 mg, 50 mg, and 75 mg, and the maximum recommended daily dose is 75 mg. For children aged ≥6 years, the recommended starting dose is 50 mg daily with dose adjustments made in 25 mg increments, while the starting dose for children 1–5 years is 25 mg. Monitoring of liver function tests and blood count are recommended during therapy as liver toxicity is a reported toxicity and dosing is based on platelet count parameters with the goal of therapy to maintain a platelet count between 50×10⁹/L and 200×10⁹/L. Powder for oral suspension is in development for use in young children who cannot swallow tablets, but it has not yet become readily available outside of clinical trials.

It is important to point out that all of the clinical trials were conducted with eltrombopag dosed per weight, while this dosing strategy does not take patient weight into account.

**Figure 1** Simple schematic representing the location of TPO and eltrombopag binding and signaling through TPO receptor when ligands bind.

**Abbreviation:** TPO, thrombopoietin.

**Figure 2** Chemical structure of eltrombopag.
Therefore, clinicians may wish to consider patient weight when making starting dose decisions, particularly in very children or in children near the age where the recommended dose changes.

**Pediatric clinical trial results**

Two randomized, placebo-controlled, clinical trials have been performed in pediatric patients with ITP of >6-month duration using eltrombopag (because the definition of chronic ITP was changed from >6-month to >12-month duration between the time of the clinical trials design and completion, after the publication of new guidelines). The first study, called PETIT was a three-part, multicenter, international study performed at 22 centers across North America and the European Union. Children and adolescents aged 1–17 years were enrolled initially in an open-label dose-finding phase (15 patients). The next 67 patients were then assigned to a randomized, placebo-controlled study (2:1, eltrombopag:placebo). The second study, PETIT2, was a randomized, placebo-controlled study in children and adolescents aged 1–17 years. The primary end point in PETIT was to compare the percentage of patients who achieved a platelet count of \( \geq 50 \times 10^9/L \) at least once while on therapy (62% vs 32% placebo), while in PETIT2 it was to assess the ability of eltrombopag to produce sustained platelet count response (defined as platelet count of \( \geq 50 \times 10^9/L \) without rescue for \( \geq 6 \) weeks out of 8 weeks between weeks 5 and 12; 40% vs 3% for placebo). Both studies had an open-label portion as well, and during the open-label portion \( \sim 80\% \) of patients (54 [81%] patients in PETIT and 70 [80%] patients in PETIT2) had a platelet count of \( \geq 50 \times 10^9/L \) at least once. Clinical data also showed that eltrombopag was able to reduce bleeding symptoms (which do not always correlate with platelet count) in both PETIT (eltrombopag vs placebo: 14 [31%] vs 18 [82%]) and PETIT2 (23 [37%] vs 16 [55%]).

**Other pediatric studies**

Several smaller studies have been published examining the use of eltrombopag in clinical practice outside of clinical trials. Most of these are case reports; therefore, the data presented must be carefully interpreted. However, one study reports data from a larger cohort of patients treated at two larger medical centers treating patients with eltrombopag while not part of a clinical trial. Ramaswamy et al reported the use of TPO RAs in 33 patients. Of these, 12 children (mean age, 14.5 years; range, 3–19 years) received eltrombopag and 9/12 achieved a platelet count of \( \geq 50 \times 10^9/L \) at least twice during the treatment duration and 57% had a platelet count of \( \geq 50 \times 10^9/L \) for \( >50\% \) of the time they were treated. One of these patients developed a thrombosis (provoked after an ankle fracture), but there were otherwise no serious adverse events (AEs).

Two randomized, placebo-controlled studies in pediatric patients have been published with the other TPO RA, romiplostim, which has not yet received FDA approval. These studies show that, like eltrombopag, treatment with romiplostim can result in increases in platelet count in children with chronic ITP. Bussel et al reported on a group of 22 children aged 12 months to \(<18\) years with ITP of \( \geq 6\) month duration who were randomized to romiplostim (\( n=17 \)) or placebo (\( n=5 \)) for 12 weeks. In this study, 88% of patients in the treatment group had a platelet count response (defined as a platelet count of \( \geq 50 \times 10^9/L \) for 2 consecutive weeks). There were no serious AEs in this study, and the AEs reported were mostly headaches and epistaxis. Interestingly, during the study, there was more bleeding related to AEs in the romiplostim-treated patients (71% vs 40% of patients), but the majority of these events were in the first 6 weeks of the study during dose titration in the treatment arm.

The second study, published in the same year, is a single-institution, randomized, single-blind, placebo-controlled trial of romiplostim in 18 non-splenectomized pediatric patients aged 2.5–6 years with ITP of \( >12\) month duration. In this study, the most common AEs in the romiplostim-treated patients were headache, epistaxis, cough, and vomiting (which all occurred less frequently than in the placebo group: % vs 16%, respectively) and rash, which only occurred in the romiplostim group, and there were no serious AEs. The authors reported that 83.3% of patients maintained a platelet count of \( \geq 50 \times 10^9/L \) for the study duration.

**Side effects/monitoring**

**Adverse reactions**

In the adult studies, the most commonly reported AEs were nausea, diarrhea, and upper respiratory infection. In pediatric trials, the most commonly reported AEs were headaches, upper respiratory infection symptoms, and diarrhea. A new toxicity reported in the pediatric trials that had not been seen in the previous adult trials was neutropenia (there were three events in the two pediatric trials all of which were grade 4).

**Liver toxicity**

A dose-limiting toxicity of eltrombopag that was noted in clinical trials, which is not associated with romiplostim, was elevation of liver enzymes. It is recommended that transaminases
Eltrombopag has recently been approved for use in children ≥1 year of age with chronic ITP with insufficient response to first line therapy. The available pediatric data suggest that this medication is effective at raising platelet count in many patients with ITP and is as effective in pediatric patients as it is in adults with chronic ITP. Patients should be monitored for the development of elevated serum transaminases and cataracts. Some patients, particularly those with underlying or acquired risk factors, may be at increased risk of thrombosis with therapy and a careful risk/benefit discussion should be held with families prior to initiation of therapy.

**Cataracts**

Ophthalmologic screening for cataract development is also recommended prior to initiation, and screening of patients for signs and symptoms of development of cataracts is recommended during therapy. In adult studies, treatment with daily eltrombopag was associated with the development of cataracts in some patients, but many of these patients were also treated with significant amounts of prior steroid therapy so that the true contribution of eltrombopag alone in this setting is still unclear. However, rodent toxicology studies did demonstrate cataract development suggesting that eltrombopag alone may contribute to this toxicity and monitoring is recommended. In pediatric studies, two of the 92 patients enrolled in PETIT2 were found to have developed new cataracts during the study duration.\(^{15}\)

**Thrombosis/thromboembolism**

In adult trials with eltrombopag, there were both venous and arterial thrombotic events reported in patients, and these were observed even at low or normal platelet count. In the two reported pediatric clinical trials, there were no reported thrombotic complications. The study by Ramaswamy et al reported one episode of provoked deep venous thrombosis in a pediatric patient with an ankle fracture.\(^{18}\) A recent review of off-label use of TPO RAs in pediatric patients with ITP prepared by the pediatric ITP Consortium of North America, a large collaborative of pediatric treating institutions across USA and Canada, noted two thrombotic events in 97 patients treated with TPO RAs and both of these events were in patients (n=33) treated with eltrombopag and in patients with underlying risk factors for thrombosis.\(^ {22}\) This suggests that the risk of thrombosis in patients being treated with eltrombopag may be increased in those patients with underlying risk factors and should be carefully weighed in susceptible patients.

**Summary**

Eltrombopag has recently been approved for use in children ≥1 year of age with chronic ITP with insufficient response

References

13. Wire MB, Bruce J, Gauvin J, et al. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS. *Clin Ther*. 2012;34:699–709.


